Single-cell transcriptomics of NRAS-mutated melanoma transitioning to drug resistance reveals P2RX7 as an indicator of early drug response
Summary: Treatment options for patients with NRAS-mutant melanoma are limited and lack an efficient targeted drug combination that significantly increases overall and progression-free survival. In addition, targeted therapy success is hampered by the inevitable emergence of drug resistance. A thorou...
Main Authors: | Tijana Randic, Stefano Magni, Demetra Philippidou, Christiane Margue, Kamil Grzyb, Jasmin Renate Preis, Joanna Patrycja Wroblewska, Petr V. Nazarov, Michel Mittelbronn, Katrin B.M. Frauenknecht, Alexander Skupin, Stephanie Kreis |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-07-01
|
Series: | Cell Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211124723007076 |
Similar Items
-
MEK inhibitors for the treatment of NRAS mutant melanoma
by: Sarkisian S, et al.
Published: (2018-08-01) -
Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma
by: Qian Zhao, et al.
Published: (2022-11-01) -
Case report: Therapeutic potential of T-VEC in combination with MEK inhibitors in melanoma patients with NRAS mutation
by: Sonja C. S. Simon, et al.
Published: (2023-03-01) -
Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
by: Markus V. Heppt, et al.
Published: (2017-08-01) -
Potential Rx-to-OTC Switch Drug Candidates
by: Victor Phan, et al.
Published: (2016-02-01)